Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
573 stopped studies mapped to Multiple Myeloma and descendants · 91% state a reason
Over the 573 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT01332617 | Phase II Study of Simvastatin for Relapsed/Refractory Myeloma | Phase 2 | withdrawn | Apr 11, 2011 | University of Louisville | Investigators no longer interested in activating study | Other (stated, no rule matched) |
| NCT00963872 | Donor Umbilical Cord Blood Transplant After Fludarabine Phosphate, Cyclophosphamide, and… | Phase 1 / Phase 2 | terminated | Aug 24, 2009 | Masonic Cancer Center, University of Minnesota | Lack of efficacy after interim analysis | Efficacy / futility |
| NCT03100877 | Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating… | Phase 1 / Phase 2 | withdrawn | Apr 4, 2017 | City of Hope Medical Center | Feasibility Issues | Other (stated, no rule matched) |
| NCT01343368 | Preservation of Ovarian Function After Hematopoietic Cell Transplant | Phase 2 | terminated | Apr 28, 2011 | Masonic Cancer Center, University of Minnesota | not stated | Not stated |
| NCT01518465 | Dalteparin, Lenalidomide, and Low-Dose Dexamethasone in Treating Patients With Previously… | Phase 2 | terminated | Jan 26, 2012 | University of Southern California | Insufficient Accrual | Enrollment / accrual |
| NCT01969565 | Study of Carfilzomib in Combination w/Dexamethasone in Patients w/Newly Diagnosed… | Phase 2 | terminated | Oct 25, 2013 | Emory University | Logistical reasons | Other (stated, no rule matched) |
| NCT00574080 | UARK 2006-15: A Study of Tandem Transplants With or Without Bortezomib and Thalidomide | Phase 3 | terminated | Dec 14, 2007 | University of Arkansas | low accrual | Enrollment / accrual |
| NCT00657553 | Preemptive Strike With Bortezomib in Multiple Myeloma Patients(2007-77) | Phase 3 | terminated | Apr 14, 2008 | University of Arkansas | Due to poor accrual | Enrollment / accrual |
| NCT00113919 | UARK 2003-25: A Study of Intravenous (IV) Busulfan (Busulfex®) in Multiple Myeloma… | Phase 1 / Phase 2 | terminated | Jun 13, 2005 | University of Arkansas | Due to poor accrual | Enrollment / accrual |
| NCT01646762 | Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Relapsed… | Phase 2 | terminated | Jul 20, 2012 | Mayo Clinic | Did not pass the Stage 1 interim analysis. | Efficacy / futility |
| NCT01251172 | RO4929097 After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma | Phase 2 | withdrawn | Dec 1, 2010 | National Cancer Institute (NCI) | Lack of Drug Supply | Drug supply |
| NCT03283046 | Study of Lenalidomide/Dexamethasone With Nivolumab and Ipilimumab in Patients With Newly… | Phase 1 | withdrawn | Sep 14, 2017 | M.D. Anderson Cancer Center | Similar to another study. | Other (stated, no rule matched) |
| NCT00849251 | Pegylated Liposomal Doxorubicin Hydrochloride, Bortezomib, Cyclophosphamide, and… | Phase 1 / Phase 2 | terminated | Feb 23, 2009 | University of Washington | One of the study drugs is not available. | Other (stated, no rule matched) |
| NCT00857324 | Study of Vorinostat Plus Melphalan and Prednisone (Zmp) in Advanced, Refractory Multiple… | Phase 1 / Phase 2 | terminated | Mar 6, 2009 | Tiziana Marangon | The Phase I of the study was completed, but Phase 2 has not been activated | Other (stated, no rule matched) |
| NCT01720043 | Hemostatic Effects of VELCADE®* Treatment in Multiple Myeloma Patients | Phase 2 | terminated | Nov 1, 2012 | University of Utah | Slow Accrual | Enrollment / accrual |
| NCT03191981 | Pembrolizumab Cyclophosphamide and Lenalidomide for Patients With Relapsed Multiple…(MUKfourteen) | Phase 1 / Phase 2 | withdrawn | Jun 19, 2017 | University of Leeds | Withdrawal of pharma support prior to opening to recruitment | Enrollment / accrual |
| NCT00714259 | Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the… | Phase 2 / Phase 3 | terminated | Jul 14, 2008 | University of Alabama at Birmingham | Accrual goals could not be met within a timely manner | Enrollment / accrual |
| NCT00837200 | Oncaspar/Doxil/Decadron in Patients With Refractory Lymphoid Malignancies | Phase 2 | terminated | Feb 5, 2009 | Milton S. Hershey Medical Center | PI said to close accrual do to funding | Enrollment / accrual |
| NCT00843310 | Combination of Revlimid, Melphalan and Dexamethasone as First Line Treatment for Multiple… | Phase 2 | terminated | Feb 13, 2009 | NYU Langone Health | Due to slow accrual | Enrollment / accrual |
| NCT02658396 | GO-203-2C + Bortezomib For Relapsed Or Refractory MM | Phase 1 | withdrawn | Jan 18, 2016 | Dana-Farber Cancer Institute | Study was never open due to lack of funding | Funding |
| NCT01076270 | Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A… | N/A | terminated | Feb 26, 2010 | Fred Hutchinson Cancer Center | Funding withdrawal | Funding |
| NCT01251952 | Dose Escalation Trial of Denileukin Diftitox (Ontak) Post Autologous Transplantation | Phase 1 | terminated | Dec 2, 2010 | Barbara Ann Karmanos Cancer Institute | Drug unavailable | Other (stated, no rule matched) |
| NCT01548573 | Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment | Phase 2 | terminated | Mar 8, 2012 | University of Iowa | Met study stopping rules | Other (stated, no rule matched) |
| NCT01965834 | Phase II Study to Evaluate Fenofibrate Therapy in Patients With Smoldering or Symptomatic… | Phase 2 | terminated | Oct 18, 2013 | University of Miami | Lack of adequate accrual. | Enrollment / accrual |
| NCT02619812 | Manage Diarrhea in Patients With Multiple Myeloma While Receiving Conditioning… | Phase 2 | terminated | Dec 2, 2015 | Mayo Clinic | Difficulty recruiting; pill burden and nausea were barriers | Enrollment / accrual |
| NCT02951117 | A Study of Venetoclax and ABBV-838 Combination Therapy With Dexamethasone in Participants… | Phase 1 | withdrawn | Nov 1, 2016 | AbbVie | No participants enrolled | Enrollment / accrual |
| NCT00676806 | A Phase II Study of Umbilical Cord Blood Transplantation | Phase 2 | terminated | May 13, 2008 | Tufts Medical Center | Slow accrual | Enrollment / accrual |
| NCT01018927 | Detecting Early Myocardial Infiltration w/Amyloid & Light Chain Deposition Disease in… | — | terminated | Nov 25, 2009 | University of Arkansas | PI does not have time to continue study | Other (stated, no rule matched) |
| NCT01729338 | Velcade + Cyclophosphamide in Newly Diagnosed Multiple Myeloma | Phase 2 | terminated | Nov 20, 2012 | Duke University | not stated | Not stated |
| NCT00934232 | Busulfan in Multiple Myeloma | Phase 1 | terminated | Jul 8, 2009 | Guido Tricot | PI left the institution | Investigator |
| NCT01610999 | Pilot Study of Lymphoid Tumor Microenvironmental Dysruption Prior to Autologous Stem Cell… | Phase 1 | terminated | Jun 4, 2012 | Tufts Medical Center | Unavailability of study article | Other (stated, no rule matched) |
| NCT00681044 | HD Melphalan and SCT in Patients With IGDD or LCDD | Phase 2 | terminated | May 20, 2008 | Boston Medical Center | Poor accrual | Enrollment / accrual |
| NCT02802163 | Induction Therapy for Multiple Myeloma With Carfilzomib,… | Phase 1 / Phase 2 | withdrawn | Jun 16, 2016 | H. Lee Moffitt Cancer Center and Research Institute | study drug unavailable | Other (stated, no rule matched) |
| NCT00109889 | S0340 MRI and Fludeoxyglucose F18 PET in Diagnosing Solitary Plasmacytoma | Phase 2 | terminated | May 4, 2005 | SWOG Cancer Research Network | poor accrual | Enrollment / accrual |
| NCT01750762 | Lenalidomide After Allo Transplant | Phase 1 | terminated | Dec 17, 2012 | Beth Israel Deaconess Medical Center | not stated | Not stated |
| NCT01534143 | High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma… | Phase 2 | terminated | Feb 16, 2012 | Barbara Ann Karmanos Cancer Institute | Data was not collected, because funding was unavailable to continue study. | Funding |
| NCT00698685 | Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem… | Phase 2 | terminated | Jun 17, 2008 | University of Arizona | Pentostatin/alemtuzumab regimen had greater risk of graft failure. | Other (stated, no rule matched) |
| NCT01207765 | Zevalin for Patients With Incomplete Response to Chemo Prior to Autologous Stem Cell… | Phase 2 | terminated | Sep 23, 2010 | Tufts Medical Center | changes in practice | Other (stated, no rule matched) |
| NCT01484314 | Eltrombopag for Thrombocytopenia in Patients With Relapsed Multiple Myeloma | Phase 2 | terminated | Dec 2, 2011 | Dana-Farber Cancer Institute | Low accrual. | Enrollment / accrual |
| NCT00560352 | Safety Study of Dasatinib With Bortezomib (Velcade®) and Dexamethasone for Multiple… | Phase 1 | terminated | Nov 19, 2007 | Bristol-Myers Squibb | not stated | Not stated |
| NCT01954784 | Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With… | Phase 1 | terminated | Oct 7, 2013 | Case Comprehensive Cancer Center | Funding unavailable | Funding |
| NCT02254551 | Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or… | Phase 2 | terminated | Oct 2, 2014 | SCRI Development Innovations, LLC | Safety lead-in data did not support continuation of study. | Safety / toxicity |
| NCT02402725 | A Open-label Study of Ultra-High Dose Dexamethasone for Relapsed Multiple Myeloma(UltraDex) | Phase 2 | withdrawn | Mar 30, 2015 | Boston Medical Center | poor accrual | Enrollment / accrual |
| NCT01504490 | Phase I Study of CS-7017 and Bexarotene | Phase 1 | terminated | Jan 5, 2012 | Georgetown University | Drug no longer available | Other (stated, no rule matched) |
| NCT00075608 | 2nd Autologous Stem Cell Transplant in Patients With Persistent/Recurrent (AL) Amyloidosis | Phase 2 | terminated | Jan 12, 2004 | Boston Medical Center | poor accrual | Enrollment / accrual |
| NCT02578121 | UARK 2015-03 A Phase II Trial of a Novel Proteasome/IMiD Combination | Phase 2 | withdrawn | Oct 16, 2015 | University of Arkansas | Investigator decided to close study without enrollment | Investigator |
| NCT01410929 | Evaluation of Vertebral Compression Fracture Fixation With RF Kyphoplasty in Patients…(MM) | Phase 4 | withdrawn | Aug 5, 2011 | DFINE Inc. | not stated | Not stated |
| NCT01695330 | Subcutaneous (SC) Bortezomib-Regimens for Patients With RR MM Failing Prior IV… | Phase 2 | terminated | Sep 27, 2012 | Oncotherapeutics | Terminated by Sponsor of this study. | Other (stated, no rule matched) |
| NCT01947309 | Observational Registry Study of Chinese Patients Treated With Revlimid (Lenalidomide) | — | terminated | Sep 20, 2013 | Celgene | Business Decision | Sponsor / business decision |
| NCT01812720 | Carfilzomib and Dexamethasone in Treating Patients With Multiple Myeloma Who Previously…(CARAMEL 2) | Phase 2 | withdrawn | Mar 18, 2013 | Mayo Clinic | not stated | Not stated |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Dec 29, 2017source: clinicaltrials